Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Market Closed 07-24 16:00:00 EDT

9.56

-0.30

-3.04%

盘后9.58

+0.02+0.21%

19:34 EDT

High9.97	Low9.46	Vol1.01M
Open9.86	D1 Closing9.86	Amplitude5.17%
Mkt Cap700.22M	Tradable Cap543.09M	Total Shares73.24M
T/O9.75M	T/O Rate1.78%	Tradable Shares56.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":9.56,"timestamp":1784923200000,"preClose":9.86,"halted":0,"volume":1012021,"hourTrading":{"tag":"盘后","latestPrice":9.58,"preClose":9.56,"latestTime":"19:34 EDT","volume":35032,"amount":334998.481,"timestamp":1784936050948,"change":0.02,"changeRate":0.002092,"amplitude":0.00523},"delay":0,"changeRate":-0.030425963488843705,"floatShares":56808500,"shares":73244500,"eps":-0.973062,"marketStatus":"Market Closed","change":-0.3,"latestTime":"07-24 16:00:00 EDT","open":9.86,"high":9.965,"low":9.455,"amount":9752538.722616,"amplitude":0.051724,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.973062,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":9.86,"preHourTrading":{"tag":"盘前","latestPrice":10.02,"preClose":9.86,"latestTime":"09:28 EDT","volume":1973,"amount":19664.370128,"timestamp":1784899714025,"change":0.16,"changeRate":0.016227,"amplitude":0.116633},"postHourTrading":{"tag":"盘后","latestPrice":9.58,"preClose":9.56,"latestTime":"19:34 EDT","volume":35032,"amount":334998.481,"timestamp":1784936050948,"change":0.02,"changeRate":0.002092,"amplitude":0.00523},"volumeRatio":0.7999338883094103,"impliedVol":1.2071,"impliedVolPercentile":0.5936},"requestUrl":"/m/hq/s/CADL/wiki","defaultTab":"wiki","newsList":[{"id":"2651134131","title":"Candel Therapeutics Inc : Stifel Initiates Coverage with Buy Rating; Target Price $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2651134131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651134131?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:34","pubTimestamp":1783938869,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651118933","title":"Candel Therapeutics Initiated at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2651118933","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651118933?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:04","pubTimestamp":1783937040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CADL/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 06:04 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","BK4139","BK4127","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651190948","title":"Candel Therapeutics initiated with a Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2651190948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651190948?lang=en_us&edition=fundamental","pubTime":"2026-07-13 17:40","pubTimestamp":1783935623,"startTime":"0","endTime":"0","summary":"Stifel analyst Stephen Willey initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $22 price target The firm views the company’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4539","BK4127","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915496","title":"Candel Therapeutics Files Form 3 for Chief Commercial Officer Mark E. Sims","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915496","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915496?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:12","pubTimestamp":1783541563,"startTime":"0","endTime":"0","summary":"Candel Therapeutics files Form 3 for Chief Commercial Officer Mark E. SimsCandel Therapeutics filed a Form 3 naming Mark E. Sims as chief commercial officer in an initial statement of beneficial owner","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL5Ysjp9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915969","title":"Candel Therapeutics Grants New CCO Mark Sims Options for 285,000 Shares at $10.03 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915969","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915969?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:05","pubTimestamp":1783541126,"startTime":"0","endTime":"0","summary":"Candel Therapeutics grants new CCO Mark Sims options for 285,000 shares at $10.03 eachCandel Therapeutics granted new Chief Commercial Officer Mark Sims stock options for 285,000 common shares as an e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL8CtDwD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4585","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BN0W2W23.USD","SG9999014013.SGD","BK4539","LU2210149790.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","BCDF","SG9999014021.USD","IE00BN0W2V16.EUR","LU2095319765.USD","NDAQ","LU2210150020.SGD","CADL","BK4139","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915990","title":"Candel Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915990?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:05","pubTimestamp":1783541101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUA1RL05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650916367","title":"Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650916367","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650916367?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:05","pubTimestamp":1783541100,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., July  08, 2026  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immuno","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3324419/0/en/Candel-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CADL","BK4139","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934286","title":"Candel Therapeutics Posts Corporate Presentation on Cancer Immunotherapy Pipeline Led by Can-2409 and Can-3110 Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649934286?lang=en_us&edition=fundamental","pubTime":"2026-07-08 02:12","pubTimestamp":1783447974,"startTime":"0","endTime":"0","summary":"Candel Therapeutics posts corporate presentation on cancer immunotherapy pipeline led by CAN-2409 and CAN-3110 programsCandel Therapeutics outlined late-stage plans for CAN-2409, citing a positive Pha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDLbJwvRf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4135","TRIN","CADL","DVDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649988957","title":"Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649988957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649988957?lang=en_us&edition=fundamental","pubTime":"2026-07-07 16:34","pubTimestamp":1783413277,"startTime":"0","endTime":"0","summary":"July 1 (Reuters) - Candel Therapeutics Inc::*CANDEL THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 01-JUL-202620:05:00.217 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nRSD25jcvq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648269285","title":"Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Common Shares for $70,151.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2648269285","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648269285?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:22","pubTimestamp":1782937376,"startTime":"0","endTime":"0","summary":"Candel Therapeutics CTO Seshu Tyagarajan sells 7,000 common shares for $70,151.20Candel Therapeutics Chief Technology Officer Seshu Tyagarajan sold 7,000 common shares on June 29, 2026.Sale priced at ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL2wXt9Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Common Shares for $70,151.20","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648525266","title":"Candel Therapeutics Grants New Hire Options for 25,000 Shares at $10.3 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2648525266","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648525266?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:05","pubTimestamp":1782936335,"startTime":"0","endTime":"0","summary":"Candel Therapeutics grants new hire options for 25,000 shares at $10.3 eachCandel Therapeutics granted one new employee stock options to buy 25,000 common shares, priced at USD 10.3 per share.Award is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL14vjDy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","SG9999014039.USD","LU2210150020.SGD","BK4112","BK4539","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00B64PRP62.GBP","CADL","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","IE00BKPKM429.USD","BK4139","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648526897","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648526897","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648526897?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:05","pubTimestamp":1782936300,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., July  01, 2026  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immuno","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/01/3320980/0/en/Candel-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647568931","title":"Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2647568931","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647568931?lang=en_us&edition=fundamental","pubTime":"2026-06-30 23:56","pubTimestamp":1782834960,"startTime":"0","endTime":"0","summary":"Shares of Candel Therapeutics rose after the company said it was initiating a pivotal Phase 3 trial to evaluate a lung-cancer treatment.Shares were up 8.4% to $11.23 in trading midday Tuesday. The stock has nearly doubled in value this year.The company said Tuesday that it had engaged the clinical-research organization Parexel International to help execute the trial, which will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab for patients with metastatic, non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy.The trial is expected to enroll patients across 150 sites, with a primary endpoint of overall survival and secondary endpoints including safety and quality-of-life assessments, said Candel.The drug has been granted fast-track designation by the Food and Drug Administration, the biopharmaceutical company said.\"Building on our completed Phase 2 clinical t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553011","title":"Candel Therapeutics Launches Phase 3 Aurora Trial of Can-2409 Combo in Advanced NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553011?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:06","pubTimestamp":1782821166,"startTime":"0","endTime":"0","summary":"Candel Therapeutics launches Phase 3 AURORA trial of CAN-2409 combo in advanced NSCLCCandel Therapeutics launched the global pivotal Phase 3 AURORA trial of CAN-2409 with valacyclovir alongside contin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL6c4r0F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SG9999014013.SGD","CADL","SG9999014021.USD","BK4139","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","NDAQ","BK4112","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD","BK4539","IE00BKPKM429.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553449","title":"Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec (can-2409) in Advanced Non-small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553449?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:05","pubTimestamp":1782821100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA7BYCKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870624","title":"Candel Therapeutics Names Mark Sims Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870624","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870624?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:05","pubTimestamp":1782389116,"startTime":"0","endTime":"0","summary":"Candel Therapeutics names Mark Sims chief commercial officerCandel named Mark Sims chief commercial officer, effective July 6, 2026, to lead launch readiness for aglatimagene besadenovec in localized ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL1dydSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870616","title":"Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870616?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:05","pubTimestamp":1782389100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUABQTFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646891849","title":"Candel Therapeutics Stockholders Approve Directors and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2646891849","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646891849?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:48","pubTimestamp":1782334092,"startTime":"0","endTime":"0","summary":"The latest update is out from Candel Therapeutics ( ($CADL) ). Candel Therapeutics, Inc. held its Annual Meeting of Stockholders on June 23, 2026, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-stockholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-stockholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646845765","title":"Candel Therapeutics Shareholders Elected Four Class II Directors at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2646845765","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646845765?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:27","pubTimestamp":1782332869,"startTime":"0","endTime":"0","summary":"Candel Therapeutics shareholders elected four Class II directors at annual meetingCandel Therapeutics held its annual shareholder meeting on June 23, 2026.Shareholders backed the selection of four dir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL7jccTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644798004","title":"Candel Therapeutics Updates Employment Agreement with Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2644798004","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644798004?lang=en_us&edition=fundamental","pubTime":"2026-06-17 05:13","pubTimestamp":1781644399,"startTime":"0","endTime":"0","summary":"An announcement from Candel Therapeutics ( ($CADL) ) is now available. On June 12, 2026, Candel Therapeutics entered into a new employment agreemen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-updates-employment-agreement-with-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-updates-employment-agreement-with-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":-0.0609},{"period":"1month","weight":0.0313},{"period":"3month","weight":0.4708},{"period":"6month","weight":0.5419},{"period":"1year","weight":0.3657},{"period":"ytd","weight":0.692}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.056687},{"month":2,"riseRate":0.4,"avgChangeRate":0.052018},{"month":3,"riseRate":0.2,"avgChangeRate":-0.120448},{"month":4,"riseRate":0.4,"avgChangeRate":0.650234},{"month":5,"riseRate":1,"avgChangeRate":0.18781},{"month":6,"riseRate":0.2,"avgChangeRate":-0.088023},{"month":7,"riseRate":0.2,"avgChangeRate":-0.005549},{"month":8,"riseRate":0.8,"avgChangeRate":0.068985},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01705},{"month":10,"riseRate":0.4,"avgChangeRate":-0.110246},{"month":11,"riseRate":0,"avgChangeRate":-0.079739},{"month":12,"riseRate":0.8,"avgChangeRate":0.288433}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}